SIMABS NV has developed a continuous bioprocessing platform for the rapid and cost-effective development and GMP manufacturing of monoclonal and bispecific antibodies, addressing the need for high-quality biologics in personalized medicine. Their integrated approach offers a complete solution, including cell line development and regulatory support, enabling biopharmaceutical companies to accelerate their product development timelines while reducing costs.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional batch processes for manufacturing biologics can be slow, costly, and result in variability in product quality. This poses challenges for biopharmaceutical companies aiming to rapidly develop and manufacture high-quality monoclonal and bispecific antibodies, especially for personalized medicine applications.
Solution
simAbs NV offers a continuous bioprocessing platform designed for the rapid and cost-effective development and GMP manufacturing of biologics. Their integrated platform provides a complete solution encompassing cell line development, process development, and GMP manufacturing, all supported by quality and regulatory assistance. By utilizing continuous manufacturing processes, simAbs enables biopharmaceutical companies to accelerate their product development timelines while maintaining consistently high product quality and reducing overall costs. The platform's flexibility allows for the production of various biologics, including bispecific antibodies, Fabs, antibody-drug conjugates (ADCs), nanobodies, and viral vectors.
Target Audience
The primary target audience includes biopharmaceutical companies seeking efficient and cost-effective solutions for biologics development and GMP manufacturing, particularly those focused on personalized medicine and advanced therapies.
Features
- Continuous manufacturing processes for increased speed to market and consistent product quality
- Proprietary CHO cell line technology for stable recombinant protein production in a continuous perfusion system
- GMP services covering discovery, development, and manufacturing
- Process analytical systems for real-time product quality evaluation during production
- Capability to produce bispecific antibodies, Fabs, ADCs, nanobodies, and viral vectors
- Integrated approach including project management, quality, and regulatory support